[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100500146":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":30,"responsibleParty":48,"collaborators":51,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":60,"acronym":19,"eligibilityCriteria":61,"healthyVolunteers":58,"sex":62,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":19,"studyType":68,"phases":69,"briefSummary":72,"conditions":73,"keywords":19,"overallStatus":32,"whyStopped":19,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Tianjin Medical University General Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Baricitinib","EXPERIMENTAL","Baricitinib will be taken orally with a dose of 2mg once daily until the disease relapses or week 48, with a final evaluation at week 52.",[13],"Drug: Baricitinib",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","Baricitinib will be taken orally with a dose of 4mg once daily until the disease relapses or week 48, with a final evaluation at week 52.",[9],null,[21],{"name":22,"affiliation":5,"role":23},"Qiang Liu, M.D.,PhD","PRINCIPAL_INVESTIGATOR",[25],{"name":26,"role":27,"phone":28,"phoneExt":19,"email":29},"Qiang Liu, M.D.,Ph.D.","CONTACT","+86 15022439149","qliu@tmu.edu.cn",[31],{"facility":5,"status":32,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"RECRUITING","Tianjin","Tianjin Municipality","300052","China","CN",{"type":39,"coordinates":40},"Point",[41,42],117.17667,39.14222,{"lat":42,"lon":41},[45,47],{"name":26,"role":27,"phone":46,"phoneExt":19,"email":29},"+8615022439149",{"name":26,"role":23,"phone":19,"phoneExt":19,"email":19},{"type":23,"investigatorFullName":49,"investigatorTitle":50,"investigatorAffiliation":5,"oldNameTitle":19,"oldOrganization":19},"Qiang Liu","Professor of Department of Neurology",[52,54],{"name":53,"class":6},"Tang-Du Hospital",{"name":55,"class":6},"The Second Hospital of Shandong University","100500146","phase-1-efficacy-and-safety-of-baricitinib-in-neuromyelitis-optica-spectrum-disorders-100500146",false,"NCT05792462","Efficacy and Safety of Baricitinib in Neuromyelitis Optica Spectrum Disorders","Inclusion Criteria:\n\n1. Male or female patients ≥ 18 years old;\n2. Diagnosis of NMO or NMO spectrum disorder according to the 2015 International Panel for Neuromyelitis Optica Diagnosis criteria;\n3. Clinical evidence of either at least one attack requiring rescue therapy (intravenous corticosteroids, intravenous immunoglobulin, plasma exchange, or a combination of these therapies) in the year before screening or at least two attacks requiring rescue therapy in the 2 years before screening;\n4. EDSS \\\u003C=6.0;\n5. Patients were seropositive for AQP4-IgG;\n6. Able and willing to give written informed consent and comply with the requirements of the study protocol.\n\nExclusion Criteria:\n\n1. Current evidence or known history of clinically significant infection (Herpes simplex virus, varicella-zoster virus, cytomegalovirus, Epstein-Barr virus, human immunodeficiency virus, Hepatitis viruses, Syphilis, etc);\n2. Participation in another interventional trial within the last 3 months Tumor disease currently or within last 5 years;\n3. Pregnant, breastfeeding, or child-bearing potential during the course of the study Clinically relevant heart, liver, kidney or bone marrow function disorder.\n4. Have a history of venous thromboembolism (VTE), or are considered at high risk for VTE by the investigator.","ALL","18 Years","85 Years",{"count":66,"type":67},12,"ESTIMATED","INTERVENTIONAL",[70,71],"PHASE1","PHASE2","Neuromyelitis Optica Spectrum Disorders (NMOSD) is associated with a pathological humoral immune response against the aquaporin-4(AQP-4) water channel. Baricitinib is an oral Janus kinase (JAK)1\u002FJAK2 inhibitor that blocks the upregulated JAK-STAT pathway in patients with neuroimmune disorders, which is important in bone marrow regulation of B cell proliferation and differentiation. Baricitinib may benefit some patients with NMOSD due to the important role of B cells in the pathogenesis of NMOSD. Clinical trials may be needed to observe its efficacy and safety.",[74],"NMO Spectrum Disorder","2024-10-13",{"date":77,"type":78},"2024-10-16","ACTUAL",{"date":80,"type":78},"2023-04-15",{"date":82,"type":67},"2025-12-30",{"name":5,"class":6},1]